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 Key EBV transcription factors hijack host cell factors to reprogramme B cells. 
 This is mostly directed through binding to host gene enhancers and super-enhancers.
 Binding can promote or disrupt enhancer-promoter contacts to turn genes on or off.
 EBV activation of upstream MYC enhancers may promote upstream MYC 
translocations. 
 Enhancer hub disruption by EBV can initiate long term gene silencing. 
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216 Abstract 
17 The oncogenic Epstein-Barr virus (EBV) growth transforms B cells and drives lymphoma and 
18 carcinoma development. The virus encodes four key transcription factors (EBNA2, EBNA3A, 
19 EBNA3B and EBNA3C) that hijack host cell factors to bind gene control elements and 
20 reprogramme infected B cells. These viral factors predominantly target long-range enhancers 
21 to alter the expression of host cell genes that control B cell growth and survival and facilitate 
22 virus persistence. Enhancer and super-enhancer binding by these EBNAs results in large-scale 
23 reorganisation of three-dimensional enhancer-promoter architecture to drive the 
24 overexpression of oncogenes, the silencing of tumour suppressors and the modulation of 
25 transcription, cell-cycle progression, migration and adhesion. 
26
327 Introduction
28 Epstein-Barr virus (EBV) is an oncogenic γ-herpesvirus responsible for 200,000 lymphoma 
29 and carcinoma cases worldwide per year. Despite its oncogenicity, EBV infection is usually 
30 harmless and >95% of the worldwide population carry EBV as a life-long asymptomatic 
31 infection. B cell infection by EBV results in growth transformation and the establishment of a 
32 persistent latent infection in memory B cells [1]. An effective cytotoxic T lymphocyte response 
33 controls the number of EBV-infected cells and protects from tumour outgrowth [2].
34
35 Initial B cell growth transformation by EBV in vivo and EBV infection in vitro results in the 
36 expression of all latent genes including six nuclear proteins (Epstein-Barr virus nuclear 
37 antigens; EBNAs, 1, 2, 3A, 3B, 3C and leader protein), three latent membrane proteins (LMP1, 
38 2A and 2B), numerous viral microRNAs and two highly-expressed non-coding RNAs. Five 
39 latent proteins (EBNA1, 2, 3A, 3C and LMP1) are critical for the transformation of B cells [3-
40 6]. EBNA2, 3A and 3C play key roles in the B-cell transcriptional reprogramming which is 
41 crucial for the outgrowth and survival of EBV-immortalised cells. Although not required for B 
42 cell transformation, EBNA3B cooperates in the regulation of large numbers of cellular genes 
43 [7]. This review focuses on recent advances in our understanding of how these four viral 
44 transcription factors (TFs) deregulate host cell genes through the hijacking of long-range 
45 regulatory elements and the reconfiguration of enhancer-promoter architecture to induce 
46 growth transforming cancer-promoting events. 
47
48 EBV TFs associate with host cell factors to reprogramme the B cell transcriptome
49 EBNA2, EBNA3A, EBNA3B and EBNA3C alter the expression of thousands of B cell genes 
50 involved in key cellular processes such as lymphocyte activation, signalling, apoptosis, 
451 transcription, cell cycle, cell adhesion and migration, including many proto-oncogenes and 
52 tumour suppressors. These EBV TFs do not bind DNA directly and bind gene control elements 
53 through interactions with B cell DNA-binding proteins. All four proteins bind the Notch 
54 signalling pathway TF, RBPJ (RBP-J, CBF1, CSL) [8,9]. The association of EBNA2 and 
55 EBNA3 proteins with RBPJ is mutually exclusive and EBNA2 and EBNA3 proteins 
56 competitively bind to RBPJ-bound chromatin sites in the B cell genome [10-12]. The 
57 interaction between EBNA2, EBNA3A or EBNA3C and RBPJ is critical for EBV immortalised 
58 cell growth [13-16]. EBNA2 and EBNA3C also bind the ETS family member PU.1 [17,18]. 
59 More recently, EBNA3C binding to interferon regulatory factors (IRF) 4 and 8 and EBNA3A, 
60 EBNA3B and EBNA3C binding to the Runt-related transcription factor (RUNX) partner, core 
61 binding factor β (CBF β) was demonstrated [19,20].
62
63 EBNA2 is a transcriptional activator that interacts with histone acetyl transferases (HATs), the 
64 SWI/SNF chromatin remodeller and the basal transcription machinery, although it can also 
65 repress gene transcription through unknown mechanisms [21]. EBNA3A, EBNA3B and 
66 EBNA3C comprise a family of distantly-related genes and can repress and activate 
67 transcription individually and co-operatively [7]. EBNA3A and EBNA3C associate with the 
68 co-repressors C-terminal binding proteins 1 and 2 (CtBP) [22-24] and EBNA3C also binds the 
69 histone deacetylase co-repressor complex components HDACs 1 and 2, Sin3A and NCoR 
70 [25,26]. Gene silencing by EBNA3A and EBNA3C involves recruitment of polycomb 
71 repressor complexes (PRC1 and 2) to target gene loci and the deposition of the histone H3 
72 trimethyl lysine 27 (H3K27me3) silencing mark by the PRC2 methyltransferase EZH2 [27-
73 29]. EBNA3A, EBNA3B and EBNA3C can also activate cellular genes and EBNA 3C 
74 associates with the HAT p300, implicating histone acetylation in its mechanism of gene 
75 activation [7,30].
576
77 EBV TFs predominately target long-range cellular gene regulatory elements
78 EBNA2 and EBNA3 family proteins regulate viral transcription via promoter elements [31-
79 34], but most cellular target genes do not possess EBNA-responsive promoters. Chromatin 
80 immunoprecipitation-sequencing revealed that in an EBV immortalised lymphoblastoid cell 
81 line (LCL), 86% of EBNA2 human genome binding sites were in fact outside of promoter 
82 regions (>2 kb from a TSS) [35]. Similarly in a Burkitt’s lymphoma (BL) cell line, 81% of 
83 EBNA2 and 89% of EBNA3 family binding sites were > 2kb from cell gene TSSs [36]. The 
84 majority of these EBNA binding sites coincided with histone modifications that characterise 
85 enhancer elements, indicating that EBNA2 and EBNA3 proteins were likely to reprogramme 
86 B cell transcription by predominantly targeting enhancers. A number of subsequent studies 
87 using tagged versions of EBNA3A, EBNA3B and EBNA3C confirmed these results 
88 [12,20,37,38]. Motif enrichment analysis of DNA sequences at EBNA2, 3A, 3B and 3C 
89 binding sites also identified potential new DNA targeting partners [12,20,37,38]. Of these, 
90 IRF4 and the RUNX partner CBFβ have now been confirmed as interacting proteins that are 
91 required for the targeting of specific cellular genes by EBNA3C and EBNA3B and EBNA3C, 
92 respectively [12,20].
93
94 A number of the enhancer regions bound by EBNA2 and EBNA3 proteins display 
95 characteristics of ‘super-enhancers’ [39,40]. These highly-active regulatory regions represent 
96 large clusters of individual enhancer peaks containing binding sites for multiple cell-type 
97 specific TFs and high levels of histone H3 acetylation [41]. Super-enhancers play a critical role 
98 in driving high-level expression of lineage-specific genes and specific super-enhancers are 
99 often activated in cancer cells. This makes super-enhancers an attractive target for drugs that 
100 can be used to block their activity as drivers of cancer cell growth, such as the bromodomain 
6101 inhibitor JQ1 and inhibitors of the RNA polymerase II kinase CDK7 [42-46]. RNAs transcribed 
102 at EBV super-enhancers (eRNAs) have also been shown to be important for enhancer function, 
103 in common with eRNAs found at non-viral TF bound enhancers [47,48]. 
104
105 Overlap in EBNA2, EBNA3A, EBNA3B and EBNA3C binding
106 ChIP-sequencing analysis of EBNA2, EBNA3A, EBNA3B and EBNA3C identified extensive 
107 overlap in their binding sites. This is perhaps predictable given their shared cellular TF binding 
108 partners e.g. RBPJ. It is also consistent with the co-operative and/or antagonistic nature of gene 
109 regulation by these EBNAs [7,29,49]. The extent of binding overlap was reported for a BL cell 
110 line as 25% of all binding sites shared by EBNA2 and EBNA3 family proteins, with an 
111 estimated 80% of genes closest to EBNA2 binding sites also closest to an EBNA3 protein 
112 binding site [36]. Binding analysis of individual tagged EBNA3A, EBNA3B and EBNA3C 
113 proteins in LCLs found 21-26% binding overlap between different EBNA3 proteins with 37% 
114 of genes closest to EBNA2 binding sites also closest to a binding site for an EBNA3 protein 
115 [12]. It is therefore likely that the co-regulation of B cell genes by these EBNAs is mediated 
116 via their association with the same regulatory element or to different elements that target the 
117 same gene.
118
119 EBNA2 and EBNA3 proteins regulate enhancer-promoter interactions
120 The effects of EBNA2, EBNA3A, EBNA3B and EBNA3C binding to long-range elements on 
121 the three-dimensional associations between cell gene enhancers and promoters has begun to be 
122 investigated using the chromosome conformation capture (3C) family of techniques. 
123
7124 Initial studies focused on the mechanism of activation of the MYC proto-oncogene by EBNA2, 
125 a key growth promoting event that occurs shortly after EBV infection [50]. ChIP-sequencing 
126 detected EBNA2 binding at multiple super-enhancers and enhancers in a 3 Mb region around 
127 MYC [35,36]. 3C analysis demonstrated that EBNA2 increased interactions between a -428 kb 
128 EBNA2-bound super-enhancer and the MYC promoter [35]. Further studies on the effects of 
129 EBNA2 on the wider MYC enhancer-promoter interaction landscape used 4C (circularised 
130 chromosome conformation capture) to capture all MYC promoter-interacting fragments in the 
131 absence or presence of EBNA2 [51]. 4C detected MYC promoter interactions with multiple 
132 EBNA2-bound upstream and downstream enhancers and showed that EBNA2 induced 
133 widespread changes to the three-dimensional arrangement of the MYC locus [51]. In the 
134 presence of EBNA2, MYC enhancer-promoter interactions were increased over a large 
135 upstream region encompassing multiple enhancers and super-enhancers, consistent with 
136 previous reports, but surprisingly EBNA2 reduced downstream enhancer-promoter interactions 
137 [51] (Figure 1). Upstream enhancer interactions were dependent on the presence of the 
138 SWI/SNF ATPase BRG1 which is bound and recruited by EBNA2 [51-53]. SWI/SNF is 
139 important in maintaining downstream MYC enhancer-promoter interactions in leukaemic cells 
140 and is required for the function of multiple distal lineage-specific enhancers [54,55]. Similar 
141 directional changes to MYC enhancer-promoter architecture were induced on infection of 
142 primary B cells by EBV that differed from the downstream interactions induced on short-term 
143 B cell activation by CD40 ligand and IL-4 [51]. This indicates that EBV activation of MYC 
144 involves distinct spatial reorganisation of chromatin. Multiple cell TFs are co-localised with 
145 EBNA2 at MYC enhancers including RBPJ, but which TFs are crucial for EBNA2 binding to 
146 MYC enhancers is not known. EBNA3A and EBNA3B also bind to MYC enhancers, but their 
147 effect on MYC enhancer-promoter interactions has not been studied [37,38]. 
148
8149 Interestingly, in EBV-positive BL, the MYC-immunoglobulin translocations that characterise 
150 BL have a breakpoint located in the upstream MYC enhancer region activated by EBV [51]. 
151 EBV also upregulates the expression of the activation induced cytidine deaminase enzyme 
152 (AID), known to be an inducer of MYC translocations [56,57]. It has therefore been proposed 
153 that  the specific activation of upstream MYC enhancers by EBV may increase the susceptibility 
154 of this region to translocations induced by off-target AID activity and could represent an 
155 initiating event in the genesis of BL [51].
156
157 Further studies characterised an EBNA2-bound and RBPJ-dependent RUNX3 super-enhancer 
158 97 kb upstream of the gene TSS [40]. RUNX3 is a direct target of EBNA2, likely to play an 
159 important role in promoting growth, at least in part by its downregulation of Runx1c 
160 expression, which is growth inhibitory in B cells [58-60]. Genome-wide promoter-enhancer 
161 analysis in an EBV-immortalised cell line detected high levels of interactions between the 
162 RUNX3 super-enhancer region and RUNX3 promoters, providing evidence for the presence of 
163 RUNX3 super-enhancer-promoter interactions in EBV-infected cells [40,61] (Figure 1). The 
164 RUNX3 super-enhancer is also bound by EBNA3B and EBNA3C and gene expression analysis 
165 indicates that EBNA3 proteins have a positive effect on RUNX3 expression [7,40]. Whether 
166 these EBNA3 proteins also increase RUNX3 enhancer-promoter interactions however, has not 
167 been tested.
168
169 The influence of EBNA3A, 3B and 3C binding on enhancer-promoter interactions at sites 
170 shared by EBNA2 has also been examined at other gene loci that include a distal intronic site 
171 at CTBP2 bound by all four proteins [36]. CtBP1 and 2 are transcriptional repressors that bind 
172 EBNA3A and EBNA3C and mediate the repression of a number of key cell genes including 
9173 the cyclin-dependent kinase inhibitor (CDKI) p16INK4a [22,23,62]. The repression of p16INK4a 
174 by EBNA3A and EBNA3C is a critical event required for the outgrowth of EBV-infected cells 
175 [63], so regulation of CtBP2 expression by EBV TFs may influence gene repression by EBV 
176 or modulate other functions of CtBP2. Perhaps surprisingly, EBNA3A and EBNA3B repress 
177 CtBP2 transcription (EBNA3C effects were not examined), although this is consistent with the 
178 frequent silencing of CtBP2 in B cells [36]. Repression of CTBP2 by EBNA3A was shown to 
179 involve the disruption of interactions between the gene promoter and the EBNA3-bound distal 
180 element [36] (Figure 1). Since EBNA2 binds the CTBP2 site, it may direct enhancer-promoter 
181 looping in the absence of EBNA3A, but this was not directly tested. ChIP re-ChIP experiments 
182 did however show that EBNA2 and EBNA3 proteins do not bind this site simultaneously, 
183 indicative of competitive binding that may influence the extent of enhancer-promoter looping 
184 [36].
185
186 Additional studies of shared binding sites examined a cluster of enhancer sites up to 44 kb 
187 downstream of the TSS of the gene encoding the cell-cycle kinase wee1 [36]. Wee1 
188 phosphorylates and inactivates the mitotic kinase CDK1 to prevent unscheduled or 
189 inappropriate entry into mitosis. EBV deregulation of the cell-cycle through its effects on 
190 multiple CDKIs and other cell-cycle regulators plays a critical role in EBV transformation, so 
191 Wee1 regulation may also contribute to cell-cycle disruption in infected cells [64]. Specific 
192 binding of EBNA3C to WEE1 enhancers repressed WEE1 expression consistent with the 
193 promotion of the transition from G2 into mitosis by EBV [36,65,66]. Surprisingly, repression 
194 by EBNA3C did not disrupt enhancer-promoter interactions, but promoted their formation [36] 
195 (Figure 1). Presumably this looping brings in co-repressors that associate with EBNA3C to the 
196 gene TSS, although this has not been investigated. EBNA2 also bound WEE1 enhancers and 
197 loss of EBNA2 binding at these WEE1 enhancers further reduced WEE1 expression  [36].  In 
10
198 the absence of EBNA2 it is possible that more EBNA3C is able to bind and increase the level 
199 of gene repression. Re-ChIP again confirmed mutually exclusive EBNA2 and EBNA3C 
200 binding at WEE1 [36].
201
202 Competition between EBNA3 proteins and EBNA2 binding was also observed at a 6 kb 
203 intergenic enhancer in the CXCL9, CXCL10 and CXCL11 chemokine gene cluster [11]. 
204 EBNA3A binding to this site is associated with RBPJ-dependent repression of CXCL9 and 
205 CXCL10 transcription, PRC recruitment and H3K27me3 deposition across the locus [11]. 
206 Downregulation of these chemokines is likely to involve modulation of looping between this 
207 enhancer and the gene promoters, but this was not tested. Interestingly, CXCL10 can also be 
208 repressed by EBNA3C along with the adjacent CXCL11 (if not already silenced). EBNA3C 
209 binding at the CXCL9/10 enhancer was not detected, so the mechanism of this repression 
210 remains unclear [29]. Downregulation of CXCL9, 10 and 11 may constitute an immune 
211 avoidance mechanism for EBV-infected B cells in vivo since these chemokines function as key 
212 attractors of T and NK cells. EBNA2 binding to the CXCL9/10 enhancer reduced EBNA3A 
213 binding and repression of CXCL9 and CXCL10 consistent with the competitive binding and 
214 opposing gene regulation observed at WEE1 [11,36]. 
215
216 Analysis of enhancer-promoter interactions in the repression of genes targeted by EBNA3 
217 proteins alone has thus far been examined at two gene loci; the a disintegrin and 
218 metalloprotease (ADAM) gene cluster containing ADAMDEC1 and ADAM28 and the 
219 BCL2L11 gene locus encoding the pro-apoptotic protein Bim (Figure 1). ADAM28 and 
220 ADAMDEC1 regulate B cell adhesion and migration, so their repression may provide a survival 
221 advantage to EBV-infected B cells in vivo. BCL2L11 repression by EBNA3A and EBNA3C is 
11
222 known to involve PRC recruitment, increased levels of H3K27me3 and lead to long-lasting 
223 epigenetic silencing through DNA methylation at BCL2L11 promoter CpG islands [27,67]. 
224 BCL2L11 repression is a common event in lymphoma development, often providing protection 
225 from MYC-driven apoptosis in lymphomas where MYC is overexpressed e.g. BL [68]. EBV 
226 activation of MYC and repression of BCL2L11 therefore represent lymphoma driving events.
227
228 EBNA3A and EBNA3C repress ADAMDEC1 and ADAM28 by binding to an intergenic 
229 enhancer bound by RBPJ [29,36,69]. As observed at WEE1 for EBNA3C, binding of EBNA3A 
230 and EBNA3C to the ADAM enhancer mediated gene repression via looping with the gene TSSs, 
231 presumably through the formation of a repressive hub which leads to H3K27me3 deposition 
232 across the locus [36]. EBNA3A and EBNA3C silencing of BCL2L11 was originally thought to 
233 be mediated through binding to the BCL2L11 promoter [28,36], but subsequent studies 
234 identified a large chromatin hub comprising multiple enhancers bound by EBNA3A and/or 
235 EBNA3C [51]. Repression of BCL2L11 by EBNA3A and EBNA3C involves recruitment of 
236 EZH2 (PRC2) across the enhancer-promoter hub and the disruption of all enhancer-promoter 
237 interactions (Figure 1). BCL2L11 can be de-repressed and apoptosis induced by an EZH2 
238 inhibitor [51]. Taken together, these studies demonstrate that repression of EBNA3A and 
239 EBNA3C target genes can operate through two different mechanisms, irrespective of whether 
240 EBNA2 targets the same sites; loop promotion or loop disruption (Figure 1).
241
242 Studies on the oncogenic miR-221 and miR-222 microRNA cluster provided the first evidence 
243 that EBNA3A and EBNA3C can activate transcription by promoting enhancer-promoter 
244 looping [70]. EBNA3A and EBNA3C activate expression of these microRNAs by binding to 
245 sites in and around the transcription unit of the pri-miR from which they are processed and 
12
246 promoting enhancer looping with the TSS [70] (Figure 1). Importantly induction of these miRs 
247 led to reduced expression of their key target gene p57KIP2, a key cyclin-dependent kinase 
248 inhibitor, providing another example of how EBV regulates gene expression to perturb cell-
249 cycle regulation in infected cells. 
250
251 Conclusion
252 It is clear that the targeting of long-range regulatory elements by EBV TFs in B cells induces 
253 significant changes to three-dimensional enhancer-promoter interactions to modulate the 
254 expression of multiple genes involved in a variety of B cell processes. This chromatin 
255 reorganisation is likely to be critical for the transformation of B cells and can lead to cancer-
256 driving events that include the long-term silencing of tumour suppressor genes like BCL2L11 
257 and may include the promotion of MYC gene translocations. Studying EBV enhancers has led 
258 to the identification of new regulatory hubs that may be affected in other cancers and has 
259 identified therapeutic opportunities for super-enhancer targeting or EZH2 inhibition. RBPJ 
260 plays a critical role in mediating the binding of EBV TFs to many cell gene enhancers but there 
261 is much more to learn about the roles played by other targeting co-factors and it is still unclear 
262 what determines whether a specific gene target is repressed via ‘anti-looping’ or looping.  
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268
269 Figure caption 
270 Figure 1. The effects of EBV transcription factors on enhancer-promoter interactions at 
271 different gene loci in B cells. The main EBV nuclear antigens (EBNAs) involved in 
272 regulation of specific genes are indicated next to the arrows. At transcribed genes the C-
273 terminal domain of RNA polymerase II (pol II) is shown in its hyperphosphorylated state 
274 with phosphates represented as yellow spheres. EBNA 3B (3B), EBNA3A (3A) and EBNA2 
275 (2, shown as a dimer) are shown bound to gene regulatory elements via cellular cofactors 
276 (coloured spheres). RBPJ (J) is shown at genes where it has been demonstrated to be involved 
277 in EBNA binding and gene regulation. At MYC, SWI/SNF complexes (S) are shown bound at 
278 upstream EBNA2 enhancers. An extruded loop is also formed upstream of MYC in the 
279 presence of EBNA2 as a result of interaction between two CTCF (C) bound sites. Additional 
280 coloured spheres represent various cellular co-activators or co-repressors involved in 
281 mediating enhancer-promoter interactions and gene regulation.  
282
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